vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Rollins, Inc. (ROL). Click either name above to swap in a different company.
Rollins, Inc. is the larger business by last-quarter revenue ($906.4M vs $722.5M, roughly 1.3× Amneal Pharmaceuticals, Inc.). Rollins, Inc. runs the higher net margin — 11.9% vs 10.8%, a 1.1% gap on every dollar of revenue. On growth, Rollins, Inc. posted the faster year-over-year revenue change (10.2% vs 3.9%). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (1.5% CAGR vs 0.8%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Rollins, Inc. is a North American pest control company serving residential and commercial clients. Operating globally through its wholly owned subsidiaries, Orkin, Inc., PCO Services, HomeTeam Pest Defense, Western Pest Services, Industrial Fumigant Company, TruTech, Critter Control, Crane, Waltham, OPC Services, PermaTreat, Northwest Exterminating, McCall Service and Clark Pest Control, as well UK subsidiaries Integrated Pest Management Limited, Safeguard Pest Control, NBC Environment, Europ...
AMRX vs ROL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $906.4M |
| Net Profit | $78.0M | $107.8M |
| Gross Margin | 44.3% | — |
| Operating Margin | — | 16.1% |
| Net Margin | 10.8% | 11.9% |
| Revenue YoY | 3.9% | 10.2% |
| Net Profit YoY | 217.0% | 2.5% |
| EPS (diluted) | $0.19 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $906.4M | ||
| Q4 25 | $814.3M | $912.9M | ||
| Q3 25 | $784.5M | $1.0B | ||
| Q2 25 | $724.5M | $999.5M | ||
| Q1 25 | $695.4M | $822.5M | ||
| Q4 24 | $730.5M | $832.2M | ||
| Q3 24 | $702.5M | $916.3M | ||
| Q2 24 | $701.8M | $891.9M |
| Q1 26 | $78.0M | $107.8M | ||
| Q4 25 | $35.1M | $116.4M | ||
| Q3 25 | $2.4M | $163.5M | ||
| Q2 25 | $22.4M | $141.5M | ||
| Q1 25 | $12.2M | $105.2M | ||
| Q4 24 | $-31.1M | $105.7M | ||
| Q3 24 | $-156.0K | $136.9M | ||
| Q2 24 | $6.0M | $129.4M |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
| Q1 26 | — | 16.1% | ||
| Q4 25 | 13.8% | 17.5% | ||
| Q3 25 | 9.0% | 21.9% | ||
| Q2 25 | 15.4% | 19.8% | ||
| Q1 25 | 14.4% | 17.3% | ||
| Q4 24 | 10.4% | 18.1% | ||
| Q3 24 | 12.6% | 20.9% | ||
| Q2 24 | 13.6% | 20.4% |
| Q1 26 | 10.8% | 11.9% | ||
| Q4 25 | 4.3% | 12.8% | ||
| Q3 25 | 0.3% | 15.9% | ||
| Q2 25 | 3.1% | 14.2% | ||
| Q1 25 | 1.8% | 12.8% | ||
| Q4 24 | -4.3% | 12.7% | ||
| Q3 24 | -0.0% | 14.9% | ||
| Q2 24 | 0.9% | 14.5% |
| Q1 26 | $0.19 | $0.22 | ||
| Q4 25 | $0.10 | $0.24 | ||
| Q3 25 | $0.01 | $0.34 | ||
| Q2 25 | $0.07 | $0.29 | ||
| Q1 25 | $0.04 | $0.22 | ||
| Q4 24 | $-0.10 | $0.22 | ||
| Q3 24 | $0.00 | $0.28 | ||
| Q2 24 | $0.02 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $116.5M |
| Total DebtLower is stronger | — | $650.6M |
| Stockholders' EquityBook value | — | $1.4B |
| Total Assets | — | $3.2B |
| Debt / EquityLower = less leverage | — | 0.47× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $116.5M | ||
| Q4 25 | $282.0M | $100.0M | ||
| Q3 25 | $201.2M | $127.4M | ||
| Q2 25 | $71.5M | $123.0M | ||
| Q1 25 | $59.2M | $201.2M | ||
| Q4 24 | $110.6M | $89.6M | ||
| Q3 24 | $74.0M | $95.3M | ||
| Q2 24 | $43.8M | $106.7M |
| Q1 26 | — | $650.6M | ||
| Q4 25 | $2.6B | $486.1M | ||
| Q3 25 | $2.6B | $485.7M | ||
| Q2 25 | $2.2B | $485.3M | ||
| Q1 25 | $2.2B | $485.5M | ||
| Q4 24 | $2.4B | $395.3M | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $-70.8M | $1.4B | ||
| Q3 25 | $-109.5M | $1.5B | ||
| Q2 25 | $-112.1M | $1.4B | ||
| Q1 25 | $-131.7M | $1.4B | ||
| Q4 24 | $-109.3M | $1.3B | ||
| Q3 24 | $-93.4M | $1.3B | ||
| Q2 24 | $-57.5M | $1.2B |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $3.7B | $3.1B | ||
| Q3 25 | $3.6B | $3.2B | ||
| Q2 25 | $3.4B | $3.2B | ||
| Q1 25 | $3.4B | $2.9B | ||
| Q4 24 | $3.5B | $2.8B | ||
| Q3 24 | $3.5B | $2.8B | ||
| Q2 24 | $3.5B | $2.8B |
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $118.4M |
| Free Cash FlowOCF − Capex | — | $111.2M |
| FCF MarginFCF / Revenue | — | 12.3% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | — | $621.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $118.4M | ||
| Q4 25 | $130.3M | $164.7M | ||
| Q3 25 | $118.5M | $191.3M | ||
| Q2 25 | $83.8M | $175.1M | ||
| Q1 25 | $7.4M | $146.9M | ||
| Q4 24 | $118.1M | $188.2M | ||
| Q3 24 | $141.8M | $146.9M | ||
| Q2 24 | $39.7M | $145.1M |
| Q1 26 | — | $111.2M | ||
| Q4 25 | $108.5M | $159.0M | ||
| Q3 25 | $106.2M | $182.8M | ||
| Q2 25 | $61.0M | $168.0M | ||
| Q1 25 | $-5.8M | $140.1M | ||
| Q4 24 | $102.9M | $184.0M | ||
| Q3 24 | $124.8M | $139.4M | ||
| Q2 24 | $29.0M | $136.4M |
| Q1 26 | — | 12.3% | ||
| Q4 25 | 13.3% | 17.4% | ||
| Q3 25 | 13.5% | 17.8% | ||
| Q2 25 | 8.4% | 16.8% | ||
| Q1 25 | -0.8% | 17.0% | ||
| Q4 24 | 14.1% | 22.1% | ||
| Q3 24 | 17.8% | 15.2% | ||
| Q2 24 | 4.1% | 15.3% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 2.7% | 0.6% | ||
| Q3 25 | 1.6% | 0.8% | ||
| Q2 25 | 3.2% | 0.7% | ||
| Q1 25 | 1.9% | 0.8% | ||
| Q4 24 | 2.1% | 0.5% | ||
| Q3 24 | 2.4% | 0.8% | ||
| Q2 24 | 1.5% | 1.0% |
| Q1 26 | — | 1.10× | ||
| Q4 25 | 3.72× | 1.41× | ||
| Q3 25 | 50.00× | 1.17× | ||
| Q2 25 | 3.74× | 1.24× | ||
| Q1 25 | 0.61× | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | 6.62× | 1.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
ROL
Segment breakdown not available.
